NO20076120L - Stabile nanopartikkelformuleringer - Google Patents
Stabile nanopartikkelformuleringerInfo
- Publication number
- NO20076120L NO20076120L NO20076120A NO20076120A NO20076120L NO 20076120 L NO20076120 L NO 20076120L NO 20076120 A NO20076120 A NO 20076120A NO 20076120 A NO20076120 A NO 20076120A NO 20076120 L NO20076120 L NO 20076120L
- Authority
- NO
- Norway
- Prior art keywords
- nanoparticle formulations
- stable nanoparticle
- formulations
- stable
- preparing
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940088679 drug related substance Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Optics & Photonics (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Abstract
Farmasøytisk stabile nanopartikkelformuleringer av tungt oppløselige legemiddelsubstanser, fremgangsmåter for fremstilling av slike formuleringer, og fremgangsmåter for anvendelse derav.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67808605P | 2005-05-05 | 2005-05-05 | |
PCT/US2006/017059 WO2007086911A2 (en) | 2005-05-05 | 2006-05-03 | Stable nanoparticle formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20076120L true NO20076120L (no) | 2007-11-27 |
Family
ID=38309654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20076120A NO20076120L (no) | 2005-05-05 | 2007-11-27 | Stabile nanopartikkelformuleringer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20080038359A1 (no) |
EP (1) | EP1895982A2 (no) |
JP (1) | JP5483874B2 (no) |
KR (2) | KR20140002810A (no) |
CN (1) | CN101252914B (no) |
AU (2) | AU2006336414B2 (no) |
BR (1) | BRPI0611433A2 (no) |
CA (1) | CA2606861C (no) |
HK (1) | HK1120417A1 (no) |
IL (1) | IL187128A0 (no) |
MA (1) | MA29492B1 (no) |
NO (1) | NO20076120L (no) |
NZ (1) | NZ562559A (no) |
RU (1) | RU2409352C2 (no) |
WO (1) | WO2007086911A2 (no) |
ZA (1) | ZA200708633B (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
US7923478B2 (en) * | 2006-12-28 | 2011-04-12 | Bridgestone Corporation | Nanoporous polymeric material and preparation method |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
WO2013041944A1 (en) | 2011-09-19 | 2013-03-28 | Ranbaxy Laboratories Limited | Process for the preparation of micronized candesartan cilexetil |
CN104174468B (zh) * | 2014-08-27 | 2016-06-15 | 上海延安药业有限公司 | 粘稠性药物锆珠研磨方法 |
AU2017250369A1 (en) * | 2016-04-15 | 2018-10-11 | Epizyme, Inc. | Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4263310A (en) * | 1974-03-02 | 1981-04-21 | Boehringer Ingelheim Gmbh | 8-Bromo-6-(o-chloro-phenyl)-4H-S-triazolo-[3,4,-c]-thieno-[2,3-e]-1,4-diazepines and salts thereof |
US4322440A (en) * | 1980-06-25 | 1982-03-30 | New York University | Anticonvulsive compositions and method of treating convulsive disorders |
CA2019719A1 (en) * | 1990-06-25 | 1991-12-25 | William J. Thompson | Mouthwash |
DE4131562A1 (de) * | 1991-09-18 | 1993-03-25 | Medac Klinische Spezialpraep | Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln) |
JPH05305226A (ja) * | 1992-04-28 | 1993-11-19 | Takeda Chem Ind Ltd | 粒子及びその製造法 |
US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US6391338B1 (en) * | 1995-09-07 | 2002-05-21 | Biovail Technologies Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
FR2754262B1 (fr) * | 1996-10-08 | 1998-10-30 | Synthelabo | Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique |
FR2766823B1 (fr) * | 1997-07-30 | 1999-10-08 | Synthelabo | Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique |
US6337092B1 (en) * | 1998-03-30 | 2002-01-08 | Rtp Pharma Inc. | Composition and method of preparing microparticles of water-insoluble substances |
WO1999065469A2 (en) * | 1998-06-19 | 1999-12-23 | Rtp Pharma Inc. | Processes to generate submicron particles of water-insoluble compounds |
US6200590B1 (en) * | 1998-08-10 | 2001-03-13 | Naphcare, Inc. | Controlled, phased-release suppository and its method of production |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
FR2788696B1 (fr) * | 1999-01-26 | 2004-03-05 | Synthelabo | Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US7078057B2 (en) * | 1999-12-20 | 2006-07-18 | Kerkhof Nicholas J | Process for producing nanometer particles by fluid bed spray-drying |
FR2813306B1 (fr) * | 2000-08-23 | 2005-10-21 | Sanofi Synthelabo | Aminoalkybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant |
US7105176B2 (en) * | 2000-11-29 | 2006-09-12 | Basf Aktiengesellschaft | Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds |
BR0115989A (pt) * | 2000-12-07 | 2004-01-13 | Altana Pharma Ag | Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido |
JP2004520432A (ja) * | 2001-02-05 | 2004-07-08 | ファルマシア・アンド・アップジョン・カンパニー | オキサゾリジノン抗菌薬の直腸送達のための組成物 |
GB0127832D0 (en) * | 2001-11-20 | 2002-01-09 | Jagotec Ag | Method for the preparation of pharmaceutical nanosuspensions |
AU2001298077A1 (en) * | 2001-12-06 | 2003-06-17 | Ranbaxy Laboratories Limited | Isotretinoin nanoparticulate compositions |
CN1275589C (zh) * | 2002-05-31 | 2006-09-20 | 王玉万 | 含抗寄生虫药物的缓释注射剂 |
EP1569623B1 (en) * | 2002-12-13 | 2008-10-15 | Jagotec Ag | A topical nanoparticulate spironolactone formulation |
EP1628626B2 (de) * | 2003-05-07 | 2013-12-04 | OTC GmbH | Zusammensetzungen zur gezielten freisetzung von duftstoffen und aromen |
KR100603974B1 (ko) * | 2003-12-05 | 2006-07-25 | 김갑식 | 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법 |
-
2006
- 2006-05-03 KR KR1020137031757A patent/KR20140002810A/ko not_active Application Discontinuation
- 2006-05-03 RU RU2007145055/15A patent/RU2409352C2/ru not_active IP Right Cessation
- 2006-05-03 AU AU2006336414A patent/AU2006336414B2/en not_active Ceased
- 2006-05-03 NZ NZ562559A patent/NZ562559A/en not_active IP Right Cessation
- 2006-05-03 JP JP2008510185A patent/JP5483874B2/ja not_active Expired - Fee Related
- 2006-05-03 CA CA2606861A patent/CA2606861C/en not_active Expired - Fee Related
- 2006-05-03 KR KR1020077025673A patent/KR20080015077A/ko active Application Filing
- 2006-05-03 CN CN200680015246XA patent/CN101252914B/zh not_active Expired - Fee Related
- 2006-05-03 EP EP06849767A patent/EP1895982A2/en not_active Withdrawn
- 2006-05-03 BR BRPI0611433-4A patent/BRPI0611433A2/pt not_active IP Right Cessation
- 2006-05-03 WO PCT/US2006/017059 patent/WO2007086911A2/en active Application Filing
-
2007
- 2007-10-10 ZA ZA200708633A patent/ZA200708633B/xx unknown
- 2007-10-18 US US11/874,393 patent/US20080038359A1/en not_active Abandoned
- 2007-11-01 IL IL187128A patent/IL187128A0/en not_active IP Right Cessation
- 2007-11-27 NO NO20076120A patent/NO20076120L/no not_active Application Discontinuation
- 2007-11-29 MA MA30430A patent/MA29492B1/fr unknown
-
2008
- 2008-11-07 HK HK08112250.2A patent/HK1120417A1/xx not_active IP Right Cessation
-
2010
- 2010-11-05 AU AU2010241245A patent/AU2010241245A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1895982A2 (en) | 2008-03-12 |
KR20080015077A (ko) | 2008-02-18 |
CN101252914B (zh) | 2013-03-27 |
KR20140002810A (ko) | 2014-01-08 |
MA29492B1 (fr) | 2008-05-02 |
ZA200708633B (en) | 2009-01-28 |
AU2010241245A1 (en) | 2010-11-25 |
AU2006336414B2 (en) | 2011-11-24 |
JP2008540439A (ja) | 2008-11-20 |
JP5483874B2 (ja) | 2014-05-07 |
RU2007145055A (ru) | 2009-06-10 |
BRPI0611433A2 (pt) | 2010-09-08 |
NZ562559A (en) | 2011-03-31 |
CA2606861A1 (en) | 2007-08-02 |
US20080038359A1 (en) | 2008-02-14 |
CA2606861C (en) | 2012-08-07 |
CN101252914A (zh) | 2008-08-27 |
WO2007086911A3 (en) | 2008-04-17 |
AU2006336414A1 (en) | 2007-08-02 |
IL187128A0 (en) | 2008-06-05 |
RU2409352C2 (ru) | 2011-01-20 |
WO2007086911A2 (en) | 2007-08-02 |
HK1120417A1 (en) | 2009-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200716646A (en) | (S)-N-methylnaltrexone | |
LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
WO2009012303A3 (en) | Therapeutic stable nanoparticles | |
NO20070785L (no) | Sammensetninger for levering av svaert vannloselige medikamenter. | |
NO20090305L (no) | Cyklosporin formuleringer | |
NO20085338L (no) | Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav | |
IL183274A0 (en) | Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes, pharmaceutical formulations containing the same, and use thereof as medicaments | |
NO20075136L (no) | Nye liposompreparater | |
PL1909843T3 (pl) | Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne i ich zastosowanie w dziedzinie farmacji | |
BRPI0607198A2 (pt) | composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica | |
NO20091299L (no) | Substituerte sulfonamidderivater | |
CO5660287A2 (es) | Derivados de tetrahidrocarbazol y su uso farmaceutico | |
MY149601A (en) | Masking the taste of powders | |
WO2006002077A3 (en) | Stable pharmaceutical formulations of benzimidazole compounds | |
DK1654253T3 (da) | Substituerede 3-pyrrolidinindolderivater | |
DK1543063T3 (da) | Medikament levering | |
NO20076120L (no) | Stabile nanopartikkelformuleringer | |
UA97629C2 (ru) | Фармацевтическая композиция, имеющая противоопухолевую активность, и способы | |
DK2185561T3 (da) | Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf | |
TW200640932A (en) | Clopidogrel base suitable for pharmaceutical formulation and preparation thereof | |
DK1791872T3 (da) | Biotinylerede hexadecasaccharider, farmaceutiske præparater og anvendelse heraf | |
EA200501301A1 (ru) | Ментоловые растворы лекарственных препаратов | |
ATE481392T1 (de) | Benzimidazolderivate zur behandlung entzündlicher erkrankungen | |
NO20075508L (no) | Stannsoporfinpreparater og administrering | |
DE602004022515D1 (de) | Fenofibrate tablett und verfahren zur herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |